Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02984943 · ClinicalTrials.gov registry record · NA
The Effects of Hyperbaric Oxygen on Rheumatoid Arthritis
A NA study, sponsored by David Grant U.S. Air Force Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT02984943: Completed NA study, sponsored by David Grant U.S. Air Force Medical Center.
NCT02984943 is a NA study that has completed, run by David Grant U.S. Air Force Medical Center. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02984943, a NA study, has completed, sponsored by David Grant U.S. Air Force Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this investigation is to determine the effects and ease of using hyperbaric oxygen therapy HBO2 for the treatment of rheumatoid arthritis joint pain and prevention of disease progression. In this study it is our intention to not only evaluate effects and ease of treatment but time, cost, possible adverse events and effect size in an attempt to predict an appropriate sample size and improve on the study design prior to a more extensive study.
Primary Outcome
The Pain Sleep Quality (PSQ)-3 questionnaire will be used to measure outcome. Participants will score the question "How often have you had trouble falling asleep because of pain?" by placing a slash (/) on a 10 cm line directly beneath the question. The line will have "never" and "always" at each end. A ruler will be used to determine were the slash falls. The value between, 0-10, that corresponds on the ruler with the slash will be documented. "0" is a better outcome, and "10" is a worse outcom
Interventions
- DEVICE Hyperbaric Oxygen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-01-19 |
| Est. Completion | 2019-04-10 |
| Phase | NA |
What the finished NCT02984943 record still lists
NCT02984943 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Hyperbaric Oxygen is the first listed.
NCT02984943 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02984943 about?
NCT02984943 is a clinical study titled "The Effects of Hyperbaric Oxygen on Rheumatoid Arthritis". The purpose of this investigation is to determine the effects and ease of using hyperbaric oxygen therapy HBO2 for the treatment of rheumatoid arthritis joint pain and prevention of disease progression. In this study it is our intention to not only evaluate effects and ease of treatment but time, co...
What is the current status of trial NCT02984943?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2017-01-19. Estimated completion is 2019-04-10.
What interventions are being tested in trial NCT02984943?
The interventions under investigation include: Hyperbaric Oxygen (DEVICE).
Who is sponsoring clinical trial NCT02984943?
This trial is sponsored by David Grant U.S. Air Force Medical Center, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02984943's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy